Clinical Trial Results:
             A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis
    
|     Summary | |
|     EudraCT number | 2009-015556-15 | 
|     Trial protocol | FI SE GB DE ES CZ PT HU NL SI LV AT IT DK GR | 
|     Global completion date | 
                                    17 Apr 2012
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    04 Feb 2016
                             | 
|     First version publication date | 
                                    26 Mar 2015
                             | 
|     Other versions | |
|     Summary report(s) | 101MS325_Summary | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
